Form 8-K - Current report:
SEC Accession No. 0001178913-22-002261
Filing Date
2022-06-01
Accepted
2022-06-01 16:04:49
Documents
14
Period of Report
2022-06-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K form8k.htm   iXBRL 8-K 31471
6 image1.jpg GRAPHIC 33267
  Complete submission text file 0001178913-22-002261.txt   260185

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20220601.xsd EX-101.SCH 4701
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20220601_def.xml EX-101.DEF 18329
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20220601_lab.xml EX-101.LAB 28549
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20220601_pre.xml EX-101.PRE 20565
8 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 6623
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 22987327
SIC: 2834 Pharmaceutical Preparations